Urigen Pharmaceuticals, Inc, said it has inked a partnership deal with Hyaluron Contract Manufacturing, Inc., to develop URG101, Urigen's proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).

"Urigen's development program with Hyaluron is a critical step forward for URG101," said William J. Garner, MD, president and CEO, Urigen. "Hyaluron, with its quality-focused and innovative drug development team, makes an excellent partner for us as URG101 progresses through its development. We look forward to working with the drug development team at Hyaluron to provide a solution to PBS through the commercialisation of our product."

"We are very pleased to have been selected by Urigen to undertake the development of their kit targeting PBS," said Shawn Kinney, president, HCM. "The collaborative spirit already demonstrated by both companies' employees bodes well for a successful development program."

Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialisation of therapeutic products for urological disorders. Urigen's two lead programs URG301 and URG101 target significant unmet medical needs and major market opportunities in urology. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency.

Hyaluron Contract Manufacturing (HCM) is a leader in aseptic contract manufacturing of filled liquid parenterals and medical devices. Since 1999, HCM has been offering its customers--from newly established firms to large-scale commercial enterprises--innovative and unique solutions to all their aseptic formulation/fill needs. At the core of HCM's business is a commitment to quality, regulatory compliance and on-time delivery. HCM is located in Burlington Massachusetts.